Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what potential (a) costs and (b) regulation costs the Government anticipates for medicines manufacturers in securing separate regulatory approval for products for the UK and the EU after the UK leaves the EU.

The Government has not made a decision on whether the United Kingdom will create a separate medicines approval regime once it leaves the European Union. As such, the Government is not in a position to speculate on licensing costs for a potential UK approvals regime.